Buchumschlag

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, Jessica K. Dyson, Douglas Thorburn, David Jones, Aldo J. Montano‐Loza, Marco Carbone, Pietro Invernizzi, George Mells, Emma L. Culver, Palak J. Trivedi
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter on ‘Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis’
von: Yi Pei, et al.
Veröffentlicht: (2025)

Efficacy and Safety of Obeticholic Acid as Second‐Line Therapy in Primary Biliary Cholangitis: Systematic Review and Meta‐Analysis
von: Eliabe S. Abreu, et al.
Veröffentlicht: (2025)

Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency
von: Ellina Lytvyak, et al.
Veröffentlicht: (2026)

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
von: Jörn M. Schattenberg, et al.
Veröffentlicht: (2026)

Author Response to Letter to the Editor: Tofacitinib as a Steroid‐Free Induction in Autoimmune Hepatitis: An Initial Experience
von: Ellina Lytvyak, et al.
Veröffentlicht: (2025)

Pathogenesis, Non‐Invasive Assessments and Treatment of Hepatic Fibrosis in Autoimmune Liver Diseases
von: Ellina Lytvyak, et al.
Veröffentlicht: (2025)

Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study
von: Domenico Alvaro, et al.
Veröffentlicht: (2025)

IGFBP4 is a Metric for Primary Biliary Cholangitis and Attenuates Biliary Epithelial Cell Injury
von: Xing Zhou, et al.
Veröffentlicht: (2026)

Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America—A 5‐Year Analysis
von: Adrielly Martins, et al.
Veröffentlicht: (2026)

Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis
von: Lars Bossen, et al.
Veröffentlicht: (2026)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
von: Leyu Zhou, et al.
Veröffentlicht: (2024)

Dendritic Cell‐Depleted Mice Develop the Autoimmune Biliary Disease That Serologically and Pathogenically Models Human Primary Biliary Cholangitis
von: Jiaqi Zhang, et al.
Veröffentlicht: (2025)

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis
von: Selena Z. Kuo, et al.
Veröffentlicht: (2025)

Acute Cholangitis Caused by Migration of a Pancreatic Stent Into a Biliary Stent
von: Ryo Jimbo, et al.
Veröffentlicht: (2025)

The Efficacy and Safety of Seladelpar for Primary Biliary Cholangitis: A Systematic Review and Meta‐Analysis
von: Mohamed Abuelazm, et al.
Veröffentlicht: (2025)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis
von: Ao Gao, et al.
Veröffentlicht: (2026)

The Depletion of Plasma Cells but Not CD20 + B Cells Alleviates Primary Biliary Cholangitis
von: Xue Zhang, et al.
Veröffentlicht: (2025)

Lymphocyte‐to‐Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis
von: Huiying Lin, et al.
Veröffentlicht: (2025)

Association Between Pruritus and Healthcare Utilization and Costs Among Individuals With Primary Biliary Cholangitis
von: Robert G. Gish, et al.
Veröffentlicht: (2026)

Pyroptosis Plays a Key Role Through Macrophages in Primary Biliary Cholangitis of Mice
von: Lin-Xiang Huang, et al.
Veröffentlicht: (2026)

ATF3 Mediates the Immunoregulatory Role of the Tim‐3 Pathway in Primary Biliary Cholangitis
von: Jiamin Xu, et al.
Veröffentlicht: (2026)

Book Review. Being-Here
von: Ellina Mourtazina
Veröffentlicht: (2020)

Postoperative Cholangitis After Biliary Reconstruction: Risk Factors, Timing of Occurrence, and Validity of Tokyo Guidelines
von: Kimitaka Tanaka, et al.
Veröffentlicht: (2025)

Identifying Patients With Primary Biliary Cholangitis and Cirrhosis Using Administrative Data in a National Cohort
von: Binu V. John, et al.
Veröffentlicht: (2024)

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation
von: Ellen Werner, et al.
Veröffentlicht: (2026)

Which Cells Play a Protective Role in Primary Biliary Cholangitis: Dendritic Cells or Others?
von: Zhencheng Zhang, et al.
Veröffentlicht: (2025)

An analysis of money's worth ratios in Chile / Craig Thorburn, Roberto Rocha, Marco Morales
von: Thorburn, Craig
Veröffentlicht: (2006)

Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐Analysis
von: Edoardo G. Giannini, et al.
Veröffentlicht: (2024)

Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study
von: Mariko Maxwell, et al.
Veröffentlicht: (2026)

Response to “Which Cells Play a Protective Role in Primary Biliary Cholangitis: Dendritic Cells or Others?”
von: Jiaqi Zhang, et al.
Veröffentlicht: (2025)

Correction to ‘Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study’
Veröffentlicht: (2025)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
von: Bo Li, et al.
Veröffentlicht: (2024)

Cross‐Phenotype Genome‐Wide Association Study on the Shared Genetic Susceptibility to Systemic Sclerosis and Primary Biliary Cholangitis
von: Yiming Luo, et al.
Veröffentlicht: (2025)

PPARevolution . First PPARδ Agonist and a Dual PPARα / PPARδ Activator Approved for the Treatment of Primary Biliary Cholangitis
von: Iuliana Popescu
Veröffentlicht: (2025)

Prevention of Cholangitis by Spontaneously Dislodging Biliary Stent After an Endoscopic Procedure in Patients With Asymptomatic Bile Duct Stones
von: Shinichi Nihei, et al.
Veröffentlicht: (2025)

Optimal control of pollution stock through ecological interaction of the manufacturer and the state
von: Ellina V. Grigorieva
Veröffentlicht: (2011)

Medical Costs Increase Over Time for Primary Biliary Cholangitis Patients: A 20‐Year Population‐Based Study
von: Jur‐Shan Cheng, et al.
Veröffentlicht: (2026)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
von: Conrado Fernandez‐Rodriguez, et al.
Veröffentlicht: (2024)

Pre‐Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis
von: Allyce Caines, et al.
Veröffentlicht: (2025)